Carboxymethylcell 0.5% eye DRP 30S
Ended Awarded
- Contract number
- SPE2DB26FAUAB
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $1,291
Award facts
- Contract value 100% obligated
- $1,291.13 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $1,291.13 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Carboxymethylcellulose 0.5% eye drops (30-count). The delivery order, which carries a firm fixed-price structure with no set-aside designation, was awarded on October 29, 2025, with an ultimate completion date of October 30, 2025, and will be performed in Conshohocken, Pennsylvania. This delivery order is issued under DMS Pharmaceutical Group's Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $499.9 billion contract vehicle awarded on November 13, 2025, that positions the company as a critical regional pharmaceutical supplier for Department of Defense military healthcare facilities worldwide.
The PPV-G GEN V program represents a strategic acquisition approach to consolidate pharmaceutical distribution across the Defense Logistics Agency's Medical Supply Chain division, enabling the issuance of firm fixed-price delivery orders for a comprehensive range of products including branded and generic pharmaceuticals, over-the-counter medications, biologics, vaccines, and medical consumables. DMS Pharmaceutical Group has demonstrated substantial federal contracting capability through numerous delivery orders issued by the agency between October and November 2025, with product portfolios spanning oncology treatments, immunosuppressants, emergency medications, specialty surgical products, and routine pharmaceuticals. The company's established performance and competitive positioning within unrestricted federal procurement reflect its capability to fulfill the diverse pharmaceutical requirements of the military medical system.
Quick answers
Who was awarded contract SPE2DB26FAUAB?
SPE2DB26FAUAB was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on October 29, 2025.
How much is contract SPE2DB26FAUAB worth?
The government has obligated $1,291 on SPE2DB26FAUAB.
Is contract SPE2DB26FAUAB an order under another contract?
Yes. SPE2DB26FAUAB is a delivery order under SPE2DB24D2106, an indefinite delivery contract.
Was contract SPE2DB26FAUAB competed?
The extent of competition for SPE2DB26FAUAB was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award